Vaccinex Inc. (VCNX)’s Financial Results Comparing With Codexis Inc. (NASDAQ:CDXS)

Vaccinex Inc. (NASDAQ:VCNX) and Codexis Inc. (NASDAQ:CDXS), both competing one another are Biotechnology companies. We will contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vaccinex Inc. N/A 93.47 24.47M -2.13 0.00
Codexis Inc. 66.25M 17.58 9.45M -0.89 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Vaccinex Inc. and Codexis Inc.

Profitability

Table 2 shows us Vaccinex Inc. and Codexis Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vaccinex Inc. 0.00% 0% 0%
Codexis Inc. -14.26% -25.7% -15%

Liquidity

The Current Ratio of Vaccinex Inc. is 4.8 while its Quick Ratio stands at 4.8. The Current Ratio of rival Codexis Inc. is 3.9 and its Quick Ratio is has 3.8. Vaccinex Inc. is better equipped to clear short and long-term obligations than Codexis Inc.

Analyst Recommendations

In next table is shown Vaccinex Inc. and Codexis Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Vaccinex Inc. 0 0 0 0.00
Codexis Inc. 0 0 1 3.00

Institutional & Insider Ownership

Institutional investors held 2.2% of Vaccinex Inc. shares and 81.4% of Codexis Inc. shares. About 5.6% of Vaccinex Inc.’s share are held by insiders. Comparatively, 4.1% are Codexis Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Vaccinex Inc. -6.08% -16% -46.59% 0% 0% -53.87%
Codexis Inc. -3.28% 25.22% 13.37% 47.74% 209.49% 153.89%

For the past year Vaccinex Inc. has -53.87% weaker performance while Codexis Inc. has 153.89% stronger performance.

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington's disease. The company's preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.

Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The companyÂ’s platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also improves the pharmaceuticals companies manufacturing productivity and efficiency, as well as helps in outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. Further, the company develops biocatalysts for use in the fine chemicals market, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.